74 B4 C 36 #%&' $ ./ 14U 1 / : )'"/%& '" #$. %* #& 1#/V W&, X-/2 1,*E! #G! 1%/V C YV 1 :7? #:Z2 #? :! +!" #$ %&' ( )' * -2 + :

Transcription

1 : : 1392,(&' () #*#$%)! 269 #$"!: 2 2 1! 2 3 ()& * "# $%& #%&' $! " #$%& '( ) (Pseudocatalasesuperoxide dismutase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dr.bebrahimi@yahoo.com + : # "!

2 l-f 3 74 'HW4 N 4 q@, E 84. HKH Y 94 -> N@ 4! -. J-) ;,-! < 'I4 4 -@ ;α = M -r.f 'HW4 ` ( 80 (Study power) 'HW4 8. :U)! :)< <!- - 9% 5 ( ( N ]a 'I 21,-M 5 -@ ]a H 4 f 4Y5 T -.Y +).,GM- ty! : (Helsinki statement) K<@ - 4) : %N( KG X5,F. k 9! 4I K ;@X <@ 7K '-4 'I uha4 l-f - l-f <!- \S () 9Y \' *) f. -M -. :U)! :)< ),M : ] 4 \S :U)! :)< <!- \S :U)! :)< <!- \S.! %),:! -@ \S! ( - ;H ; m uu) <!- \S. \S X-M! 32 *4 <K f \S :U)! :)<. km! - *4 v-4 KG ; ;3-. ]< 4 ;'HW4.(1-4) 4 OH) P -M SHG) : K <!- B) )<! T- ; E 4 U S@ X S@ <!- U VW.4 %4 :U)! \' -D 3[@ :K:-) <!- 79) %& 4G<!- LG>! X ^<! ]> S@ < )<! _> 3 _-a) %4 ` ;<! >.(2 ;5-6) _> :U)!! -! ' *4 : c' 9!-)!! && «:U)!», `N 4 '! 8'HW4 ;! )., \' '9f XB LS 3 4 F - : 8'HW4 3 : - ;& 3 g,.(7-10)! 890 h 3 < -j4 8N 4 h 8'HW4! & > : 4 :U)! X-! km-0 3 Fa-0 3') l@ 'HW4 3 ;, F :)< <!- 4 m4!! 74 \4-. XB 4 :U)! 8( ;, :<@ )44 'HW4 3, \-!! -%!,! '&-4 XB 1389 \ %N( 2310

3 . 90 &) 7. 9& 15 a< SPSS GX- GB) (version 15, SPSS Inc., Chicago, IL) - G GH>. 7*) 'I & 34 8-j) :. XB 4 : ' 79. E yw 4) P < M -r '4 'I Y 94 (-4 3 : 20) !!- 4:>! 3 8'4 4) 'HW4 :D> E<4 :)< <!- \S 4 : m B4.,4> 1 \& :U)! 7*) GB) ~9f - `@! ;Repeated measurement ANOVA 4> *H : 8'I E< '4,-M -@ 'HW4 84 3E 4 '4 8N) q@ ;3[@ :D> :U)! :)< <!-.F 8'4 4) 9& 8-0 M q@ HKH -,-.F,@F4 3E -j) q@ 1 'HW4 :D>,-M -@. > - 'HW4 9 '4 (8) )44 'HW4 3 \4-! 8'I B4 -@ : -? a4 ;H '4 3E f 'I & -M ) :. - - (l-f -@ - \S ) : ; G) 74! f! \S S4! \' - 7.E () ;3[@.! xn ;-%z : ' 2 ) y9( {-'4 ;] > I X-! `> :.- -. :<E 7'H mk5 M -@ 8( \S \' : ;,N H 5 24.K l-?4 >,4 -@ 4B \f, XB *4 B4-3') -: V- - E 'I & }af4 'I 7*4! : : W4 3 ;mp.-m 3') v-4 E )! <K W4 3') - - M- -@ ~. E<4 9*4 ' - <& 'I E.4 90 'I 'I -@ \f 3-) -! ]-I ;3[@.4 9*4 > {-5 3-) HKH B4 : -: V- (2 ;HKH B4 9 (1 25 : -! HKH B4 25 HKH B4 (3 ;( B4 (4 ( 50 ) {5 4) ;,Y5.( 50 U HKH 2311

4 &%$) )*+!! "# $% &'( ( ± ).1 $ &-%*! ($% #!" ) 0"( ' ( )#*.2,(. 0+( +,#- ' ( )#* ± ±2120 %&' ()* ± ±2121 %&' ( % ± ±2031 %&' ( % ± ±1861 %&' ( % P-value - ( - ;H ; m 3! 5. %F Y 94 : S@ <!- -! l-f- - _-a) : ;B N4 -j4 h ;& 3.(11)! -M&. & 4 3 'I Y 'HW4 <!-,Y5 `N 4 ' : -f,n F)'I : K :U)! :)< 4 ' I! HE. q@ h.4,n 4 'I `N F 8'I 3 '4 8N).(12) :)< <!- - 'HW4-4 8U4 :!,,N %) (12) K@ Szczurko :U)! :)< <!-! -! 890 : S@ <!-! 3. `N :! 4, 4 :U)! :)< <!-! 3 -,5. F 74 T- ;Y4 _-a) H E-4 H' `G ;8'HW4 -.4 )<! CGM :)< <!- 4 m4!! O 2 7K >,! :)<!,-! Y 94 S@ <!- <!- < :U)! ; &.! H 2 O O 2 79) S@ Y 94! S@ <!- U VW 4 m4!! ;, F 8'HW4 : - yw 4 ;!4 `G :)< <!- ;- l-f :.4 `@! > H' :U)! L<H)!,! %4! - <! yw `G ; S@ <!- G :U)! - <! H).! B _-a) Z5 B 4.(5-6) -M4 - F - F ;4 m4!! \4- uu ;Vitix ) :U)! :)< <!- 2312

5 @8N) 5! ( 3') G4 ;- -f :.@4 ;-IE 'HW4.4 -)~. h <4!! F )44 'HW4 3 ; :)< <!- : 'I4,N ] > _!-) : :U)! 8'HW4 XB.F )5 -)OG.-M4 %F :U)! 'I4 X-!,Y5 `N 4,N :U)! :)< <!- + <!- 4 -)- q@ ;-!4.(8) F :U)! :)< ;'HW4 3,H 8UK : K 8'I B4-5 -M,: ] ' ;\E 3. _4 -M,: :,N. ]a B4,:& ;-)5 -)~. h ƒ \ B References 1. Taieb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009; 360(2): Miniati A, Weng Z, Zhang B, Stratigos AJ, Nicolaidou E, Theoharides TC. Neuro-immunoendocrine processes in vitiligo pathogenesis. Int J Immunopathol Pharmacol 2012; 25(1): Patel NS, Paghdal KV, Cohen GF. Advanced treatment modalities for vitiligo. Dermatol Surg 2012; 38(3): Colucci R, Lotti T, Moretti S. Vitiligo: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother 2012; 13(13): Hazneci E, Karabulut AB, Ozturk C, Batcioglu K, Dogan G, Karaca S, et al. A comparative study of superoxide dismutase, catalase, and glutathione peroxidase activities and nitrate levels in vitiligo patients. Int J Dermatol 2005; 44(8): Arican O, Kurutas EB. Oxidative stress in the blood of patients with active localized vitiligo. Acta Dermatovenerol Alp Panonica Adriat 2008; 17(1): Gawkrodger DJ. Pseudocatalase and narrowband ultraviolet B for vitiligo: clearing the picture. Br J Dermatol 2009; 161(4): Yuksel EP, Aydin F, Senturk N, Canturk T, Turanli AY. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. Eur J Dermatol 2009; 19(4): Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009; 161(4): Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalasedismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008; 22(11): Schallreuter KU, Rokos H. Vitix--a new treatment for vitiligo? Int J Dermatol 2005; 44(11): Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med 2011; 11:

6 Journal of Isfahan Medical School Received: Vol. 31, No. 269, Special Issue (Skin Diseases and Leishmaniasis), Marcch 2014 Accepted: The Effect of PseudocatalaseSuperoxide Dismutase in Treatment of Vitiligo: A Pilot Study Abstract Farahnaz Fatemi-Naeini MD 1, Alireza Vaez-Shooshtari 2, Bahareh Ebrahimi 2, Mohammad Ali Nilforoushzadeh MD 3, Razieh Molaei 2 Original Article Background: Pseudocatalasesuperoxide dismutase (PSD) is a topical gel considered having therapeutic effects in vitiligo. This study was designed to evaluate the efficacy of this combination in vitiligo. Methods: This was a pilot randomized, double blind, placebo controlled trial on 46 symmetrical vitiligo lesions of limbs in 23 patients referring to dermatology clinics in Isfahan, Iran, in Patients were received this formula or placebo gels for the right and left lesions. Lesion area and degree of pigmentation were assessed at baseline and 2, 4, and 6 months later. Findings: There were no significant changes in lesion area and perifollicular pigmentation in each group (P = 0.05). Conclusion: The results indicated no significant therapeutic effect for pseudocatalasesuperoxide dismutase in vitiligo. Keywords: Pseudocatalasesuperoxide dismutase, Efficacy, Vitiligo Citation: Fatemi-Naeini F, Vaez-Shooshtari A, Ebrahimi B, Nilforoushzadeh MA, Molaei R. The Effect of PseudocatalaseSuperoxide Dismutase in Treatment of Vitiligo: A Pilot Study. J Isfahan Med Sch 2014; 31(269): Associate Professor, Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran 2- Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran 3- Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran AND Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Corresponding Author: Bahareh Ebrahimi, dr.bebrahimi@yahoo.com 2314